In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...

Prognostic Model of Pulmonary High-grade Neuroendocrine Carcinoma: Integrating Genomic Analysis and Poly(ADP-ribose) Polymerase-1 Expression Research Background High-grade neuroendocrine carcinoma (HGNEC) of the lung is a highly aggressive cancer with significant biological complexity. Despite its association with Notch pathway activation and inact...

Ovarian cancer is one of the most common and deadly tumor types in women. In recent years, Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown encouraging clinical results in the treatment of ovarian cancer. Numerous studies have found that patients with homologous recombination deficiency (HRD) benefit more from PARPi treatment. Therefore, ...

Scientific Research Report Background Introduction Breast cancer is the most commonly diagnosed cancer worldwide among both men and women, and it is the leading cause of cancer-related deaths in women. The standard treatment for early-stage breast cancer usually involves surgery and (neo)adjuvant chemotherapy and/or endocrine therapy, aiming to eli...

Academic Report for the Paper Titled “Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients with Advanced Prostate Cancer from Latin America: Challenges and Future Approaches” Background Prostate cancer is one of the most common cancers among men in Latin America and the Caribbean (LAC). According to the 2020 Glo...